Aspira Women's Health Q3 product revenue up 9% to $2.2M; cash burn down 56% to $3.3M

Aspira Women's Health Inc.

2023-Q3 EPS reported -$1.54 revenue$7,024,000

Product revenue $2.2M (+9% YoY); OvaSuite volume 5,783 units (+5% YoY).
OvaWatch tests reached 1,015 in Q3, now nearly 20% of total OvaSuite volume.
Cash used in operations $3.3M, down 56% from $7.5M in Q3 2022; reiterated H2 2023 target $6-8M.
Gross margin improved to 59.0% from 55.8% YoY; R&D and SG&A expenses each down >50% YoY.
Raised $4.7M gross proceeds in registered direct offering; total cash $5.4M at Sep 30.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aspira Women's Health Inc. reported the three and nine months ended September 30, 2023 results: revenue $2,217,000.

Period: the three and nine months ended September 30, 2023
Revenue: $2,217,000
Result: reported results

Exact text from the filing

leading sales at Sema4Genomics and Sonic Reference Laboratory, Inc. Third Quarter 2023 Financial Highlights Product revenue for the three months ended September 30, 2023, was $2,217,000, an increase of 9%, compared to $2,037,000 for the same period in 2022. The increase in revenue was primarily due to an increase in OvaSuite test volume compared to the prior year,

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-23-000093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.